JPMorgan says this new player in the GLP-1 market could rally 45%
This GLP-1 drug could emerge as the next big treatment and rival key competitors.
This GLP-1 drug could emerge as the next big treatment and rival key competitors.
This website uses cookies to enhance your browsing experience. By continuing to use this site, you consent to the use of cookies. Please review our Privacy Policy for more information on how we handle your data.